🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.380
0.00 (0.00%)
At close: Nov 18, 2026, 4:00 PM EST
1.390
+0.010 (0.72%)
After-hours: Nov 18, 2026, 4:20 PM EST

Inhibikase Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
---0.260.123.1
Revenue Growth
---111.03%-96.02%343.92%
Cost of Revenue
---13.6212.0311.36
Gross Profit
----13.36-11.91-8.26
Selling, General & Admin
29.0423.5611.386.736.226.51
Research & Development
46.9522.3917.21---
Operating Expenses
75.9945.9528.596.736.226.51
Operating Income
-75.99-45.95-28.59-20.09-18.13-14.77
Interest Expense
------0.02
Interest & Investment Income
3.723.721.071.060.07-
EBT Excluding Unusual Items
-70.26-42.23-27.52-19.03-18.05-14.79
Asset Writedown
-7.4-7.4----
Other Unusual Items
-0.271.37----
Pretax Income
-69.17-48.26-27.52-19.03-18.05-14.79
Net Income
-69.17-48.26-27.52-19.03-18.05-14.79
Net Income to Common
-69.17-48.26-27.52-19.03-18.05-14.79
Net Income Growth
------
Shares Outstanding (Basic)
1679824643
Shares Outstanding (Diluted)
1679824643
Shares Change
95.43%314.60%293.35%42.74%39.15%121.72%
EPS (Basic)
-0.41-0.49-1.16-3.16-4.28-4.87
EPS (Diluted)
-0.41-0.49-1.16-3.16-4.28-4.87
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-49.37-27.8-19.15-18.1-17.59-14.3
Free Cash Flow Per Share
-0.30-0.28-0.81-3.00-4.17-4.71
Gross Margin
------266.35%
Operating Margin
----7711.98%-14686.17%-476.23%
Profit Margin
----7304.73%-14625.86%-476.88%
Free Cash Flow Margin
----6947.87%-14253.37%-461.10%
EBITDA
-75.94-45.89-28.56-19.91-18.12-
D&A For EBITDA
0.050.060.030.180.01-
EBIT
-75.99-45.95-28.59-20.09-18.13-14.77
Revenue as Reported
---0.260.123.1
SEC Filings: 10-K · 10-Q